WAYNE, Pa.--(BUSINESS WIRE)--Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that 2010 aggregate revenue of its partner companies, including Clarient and Quinnova Pharmaceuticals, each of which was sold during the same period, was $403 million, up 54% from $262 million for the same partner companies in 2009. Revenue for Safeguard’s cost and equity method partner companies is reported on a one-quarter lag basis.
